EyePoint, Inc.

EYPT
About the company

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Country: United StatesPrice: $0.31Market Cap: $34.8M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

3 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

All 10 investors flag EYPT's cash flow

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILNEUTRALNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-05

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-12

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-12

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Cash Flow0% pass✗ 12▾

      All 10 investors flag EYPT's cash flow

      Free Cash Flow Proxy$-232.9M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-299.1M
      ✗LynchPositive and growing
      Operating Cash Flow$-240.1M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-65.97%, ROA=-63.73%
      ✗PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-699.0%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive2/16 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-1156.6%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency3/16 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-299.1M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-859.19%; #4395/4519 (top 97.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✗ 13▾

      All 8 investors flag EYPT's growth

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -21.1% vs Rev: -93.9%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency2/17 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-6.0%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendrevenue flat/down, operating margin -163.1% -> -776.0%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR-1.8%
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR-14.5% over 5 years
      ✗Neff7%-20% annualized
    • Verdicts0% pass✗ 13▾

      Split decision: 13 FAIL · 3 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 2)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (1/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)•SchlossNEUTRAL (4/7)•OshaughnessyNEUTRAL (Not ranked)
    • Profitability6% pass✓ 2✗ 33▾

      15 of 16 flag EYPT's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)2/22 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)2/22 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-55.8%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-776.0% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-232.9M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-315.7%
      ✗Lynch> 15%
      EBIT / Enterprise ValueN/A (EV <= 0)
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-122.4%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-63.73%
      ✗PiotroskiROA > 0
      ROA Change YoY-31.27% -> -63.73% (delta: -32.45%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-65.97%, ROA=-63.73%
      ✗PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-738.5%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-315.7%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.1x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-47.1% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency2/17 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-13642.0%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-315.7%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-163.1% (2023) -> -776.0% (2025)
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendrevenue flat/down, operating margin -163.1% -> -776.0%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-983.77%; #6062/6340 (top 95.6%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-315.67%; #4995/5226 (top 95.6%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.1806; #4121/5884 (top 70.0%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR-14.5% over 5 years
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag EYPT's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities3.30
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-7376.8x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Valuation8% pass✓ 9✗ 19▾

      12 of 13 flag EYPT's valuation — Graham, Lynch, Greenblatt +9 more

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.1x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise ValueN/A (EV <= 0)
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-122.4%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share0.1x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-900.6%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-699.0%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.1x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($0.31)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-983.77%; #6062/6340 (top 95.6%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+3.1164; #448/6449 (top 6.9%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share0.08x
      ✓SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change+259.0%
      ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.0741; #4456/5247 (top 84.9%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-859.19%; #4395/4519 (top 97.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-97.82%; #6104/6202 (top 98.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag EYPT's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio3.30
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-214.3%
      ✗Buffett> 10%
      ROIC - WACC-224.3%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-122.4%
      ✗Greenblatt> 25%
      Current Ratio Change YoY7.81 -> 8.88
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.10x -> 0.09x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities3.30
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/2 years above 12% (latest -57.8%)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Measuring and Control Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($34.8M)
    Revenue: $31.4M-27.5% YoY
    Net Income: $232.0M-77.2% YoY

    Financial Snapshot

    Operating Margin-776.0%
    Return on Equity-75.8%
    Debt / Equity--
    Current Ratio8.88
    EPS (Diluted)$-3.17
    Shares Retired−21.4% / −67.4% 2y

    Shareholder Return

    Fiscal 2025

    Issued 21.4% of shares last year, 67.4% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, operating cash flow, depreciation amortization, capex.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-05
    FY 2024
    Sources
    • 10-K · 2025-03-06
    FY 2023
    Sources
    • 10-K · 2024-03-08
    FY 2022
    Sources
    • 10-K · 2023-03-10
    FY 2021
    Sources
    • 10-K · 2023-03-10
    Market Cap$34.8Mcurrent------$1.1Best.$525.8Mest.$1.3Best.$159.8Mest.$319.0Mest.
    Revenue$2.6M↓94%$756.0K↓22%$507.0K↓90%$696.0K↓97%$31.4M↓28%$43.3M↓6%$46.0M↑11%$41.4M↑12%$36.9M
    Operating Income-$351.8M↓61%-$96.9M↓56%-$97.4M↓56%-$87.2M↓79%-$243.4M↓67%-$145.9M↓94%-$75.1M↑25%-$99.6M↓80%-$55.3M
    Net Income-$342.5M↓66%-$95.6M↓60%-$94.5M↓59%-$84.8M↓88%-$232.0M↓77%-$130.9M↓85%-$70.8M↑31%-$102.3M↓75%-$58.4M
    EPS (Diluted)--$-1.07↓26%$-1.09↓28%$-0.99↓52%$-3.17↓37%$-2.32↓27%$-1.82↑34%$-2.74↓35%$-2.03
    Gross Margin—————————
    Operating Margin-13642.0%↓2546%-12814.4%↓100%-19207.1%↓1546%-12532.5%↓6175%-776.0%↓130%-337.1%↓107%-163.1%↑32%-240.6%↓61%-149.6%
    ROE-315.7%↓207%———-75.8%↓95%-38.9%↓46%-26.6%↑75%-106.1%↓235%-31.7%
    Total Debt--------------$39.8M↑9%$36.6M
    Shareholders' Equity$108.5M↓46%$108.5M↓46%$166.4M↓32%$230.5M↓23%$306.1M↓9%$336.5M↑26%$266.3M↑176%$96.4M↓48%$184.4M
    Current Ratio3.30↓54%3.30↓54%4.50↓44%6.66↓15%8.88↑14%7.81↑43%5.45↑9%5.00↓50%10.05
    Debt / Equity———————0.41↑108%0.20
    Operating Cash Flow-$294.8M↓40%-$86.8M↓46%-$62.3M-$80.5M↓52%-$240.1M↓90%-$126.2M↓6832%$1.9M↑103%-$65.0M↓30%-$50.1M
    Free Cash Flow-$299.1M↓40%-$88.0M↓46%-$63.5M-$81.5M↓53%-$243.4M↓87%-$130.3M↓8002%-$1.6M↑98%-$67.2M↓34%-$50.3M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Measuring and Control Equipment

    EYPT vs Peers — Financial Grading

    Revenue$31.4MBottom 25%
    Net Income$232.0MBottom 25%
    ROE-75.8%Bottom 25%
    D/E—
    Op. Margin-776.0%Bottom 25%
    Curr. Ratio8.88Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    THERMO FISHER SCIENTIFIC INC.TMO$259.4B$700.22$44.6B$6.7B12.6%0.7417.4%1.893/93/93/71/3F-Score 57/11
    DANAHER CORP /DE/DHR$163.9B$233.02$24.6B$3.6B6.9%0.3519.1%1.873/94/92/71/3F-Score 54/11
    WATERS CORP /DE/WAT$90.5B$460.25$3.2B$642.6M25.1%0.5525.4%1.731/94/91/70/3F-Score 45/11
    AGILENT TECHNOLOGIES, INC.A$49.0B$173.96$6.9B$1.3B19.3%0.4521.3%1.962/95/93/71/3F-Score 55/11
    ROPER TECHNOLOGIES INCROP$47.5B$479.98$7.9B$1.5B7.7%0.4728.3%0.522/93/93/70/3F-Score 64/11
    COHERENT CORP.COHR$43.0B$218.15$5.8B$49.4M0.9%0.691.6%2.193/91/90/70/3F-Score 44/11
    TERADYNE, INCTER$39.0B$249.55$3.2B$554.0M19.8%0.0720.4%1.752/96/94/71/3F-Score 66/11
    ILLUMINA, INC.ILMN$31.3B$207.01$4.3B$850.0M31.2%0.7318.6%2.082/91/93/71/3F-Score 85/11